## Claim Amendments

1(currently amended). A compound of Formula (I) or (II)



(I)



(II)

wherein

A is nitrogen and B is carbon;

$R^0$ is ~~an aryl optionally substituted with one or more substituents or a heteroaryl optionally substituted with one or more substituents~~ a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, $(C_1$-$C_4)$alkoxy, halo-substituted $(C_1$-$C_4)$alkyl, and cyano;

$R^1$ is ~~aryl optionally substituted with one or more substituents, heteroaryl optionally substituted with one or more substituents, –CH=CH-$R^{1a}$, or –$CH_2CH_2$-$R^{1a}$, where $R^{1a}$ is a chemical moiety selected from a 3- to 8-membered partially or fully saturated carbocyclic ring(s), 3- to 6-membered partially or fully saturated heterocycle, aryl, heteroaryl, where the chemical moiety is optionally substituted with one or more substituents~~ a phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, $(C_1$-$C_4)$alkoxy, halo-substituted $(C_1$-$C_4)$alkyl, and cyano;

X is a bond;

$R^{3a}$ and $R^{3b}$ are each independently hydrogen, $(C_1$-$C_4)$alkyl, or halo-substituted $(C_1$-$C_4)$alkyl; and

$R^4$ is a ~~chemical moiety selected from the group consisting of $(C_1$-$C_8)$alkyl, aryl, heteroaryl, aryl$(C_1$-$C_4)$alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl$(C_1$-$C_3)$alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents; or a pharmaceutically acceptable salt thereof~~ $(C_1$-$C_8)$alkyl, halo-substituted $(C_1$-$C_8)$alkyl, cyclopentyl, cyclohexyl, piperidin-1-yl, pyrrolidin-1-yl, or morpholin-4-yl;

provided that when the compound is a compound of Formula (II), $R^{3a}$ and $R^{3b}$ are not both hydrogen.

2-3(cancelled).

4(previously presented). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (I); or a pharmaceutically acceptable salt thereof.

5-7(cancelled).

8(currently amended). The compound of ~~Claim 7~~ Claim 4 wherein $R^0$ and $R^1$ are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, $(C_1$-$C_4)$alkoxy, fluoro-substituted $(C_1$-$C_4)$alkyl), and cyano; or a pharmaceutically acceptable salt thereof.

9(previously presented). The compound of Claim 8 wherein $R^0$ is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and $R^1$ is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl; or a pharmaceutically acceptable salt thereof.

10(previously presented). The compound of Claim 4 selected from the group consisting of

2-(2-chloro-phenyl)-5-isopropyl-3-(4-methoxy-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

2-(2-chloro-phenyl)-5-isopropyl-3-(4-cyano-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

2-(2-chloro-phenyl)-5-isopropyl-3-(4-chloro-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-cyclohexyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-isopropyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(2,4-dichloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-5-cyclohexyl-2-(2,4-dichloro-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(3-chloro-phenyl)-5-isopropyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-cyano-phenyl)-2-(3-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

3-(4-chloro-phenyl)-2-(3-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one; and

3-(4-chloro-phenyl)-2-(3-chloro-phenyl)-5-cyclohexyl-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one; or a pharmaceutically acceptable salt thereof.

11(previously presented). The compound of Claim 10 selected from the group consisting of

2-(2-chloro-phenyl)-5-isopropyl-3-(4-cyano-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one;

2-(2-chloro-phenyl)-5-isopropyl-3-(4-chloro-phenyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one; and

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-5-(2,2,2-trifluoro-ethyl)-5,6-dihydro-2H-pyrrolo[3,4-c]pyrazol-4-one; or a pharmaceutically acceptable salt thereof.

12-30(cancelled).

31(previously presented). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (II); or a pharmaceutically acceptable salt thereof.

32-34(cancelled).

35(currently amended). The compound of ~~Claim 34~~ Claim 31 wherein $R^0$ and $R^1$ are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro, $(C_1$-$C_4)$alkoxy, fluoro-substituted $(C_1$-$C_4)$alkyl), and cyano; or a pharmaceutically acceptable salt thereof.

36(previously presented). The compound of Claim 35 wherein $R^0$ is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and $R^1$ is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl; or a pharmaceutically acceptable salt thereof.

37-41(cancelled).

42(currently amended). A compound of Formula (III) or (IV)



(III)



(IV)

wherein

A is nitrogen and B is carbon;

$R^{0a}$, $R^{0b}$, $R^{1b}$, and $R^{1c}$ are each independently halo, $(C_1$-$C_4)$alkoxy, $(C_1$-$C_4)$alkyl, halo-substituted $(C_1$-$C_4)$alkyl, or cyano;

n and m are each independently 0, 1 or 2;

X is a bond;

$R^{3a}$ and $R^{3b}$ are each independently hydrogen, $(C_1$-$C_4)$alkyl, or halo-substituted $(C_1$-$C_4)$alkyl; and

$R^4$ is ~~a chemical moiety selected from the group consisting of $(C_1$-$C_8)$alkyl, aryl, heteroaryl, aryl$(C_1$-$C_4)$alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl$(C_1$-$C_3)$alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents~~ $(C_1$-$C_8)$alkyl, halo-substituted $(C_1$-$C_8)$alkyl, cyclopentyl, cyclohexyl, piperidin-1-yl, pyrrolidin-1-yl, or morpholin-4-yl; or

a pharmaceutically acceptable salt thereof:

provided that when said compound is a compound of Formula (IV), $R^{3a}$ and $R^{3b}$ are not both hydrogen.

43(previously presented). The compound of Claim 42 wherein said compound is a compound of Formula (III); or a pharmaceutically acceptable salt thereof.

44-48(cancelled).

49(previously presented). The compound of Claim 42 wherein said compound is a compound of Formula (IV); or a pharmaceutically acceptable salt thereof.

50-54(cancelled).

55(previously presented). A pharmaceutical composition comprising (1) a compound of Claim 1, or said salt; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

56-58 (cancelled).

59(previously presented). A method for treating obesity comprising the step of administering to an animal in need of such treatment a therapeutically effective amount of a compound of Claim 1; or a pharmaceutically acceptable salt thereof.

60-63(cancelled).

64(previously presented). A method for treating obesity comprising the step of administering a pharmaceutical composition of Claim 55.

65–73 (cancelled).